1. From the Department of Ophthalmology, University of Aberdeen, Aberdeen, United Kingdom; the
2. Division of Ophthalmology, University of Bristol, Bristol, United Kingdom; the
3. Therapeutic Antibody Centre, University of Oxford, Oxford, United Kingdom; and the
4. Department of Rheumatology, School of Clinical Medical Sciences, University of Newcastle-upon-Tyne, Newcastle-upon-Tyne, United Kingdom.